DTE
50
3
AFL
46
-3
M
20
-4
USB
50
2
AXP
66
2
IVZ
46
3
RSG
68
3
EXR
57
-2
LH
42
2
KR
34
-3
UNH
61
6
TDC
75
4
MRK
22
3
TAP
58
-2
IFF
53
2
ALLE
37
5
DOV
61
-2
QRVO
6
2
PSA
51
-4
HON
65
-2
DTE
50
3
AFL
46
-3
M
20
-4
USB
50
2
AXP
66
2
IVZ
46
3
RSG
68
3
EXR
57
-2
LH
42
2
KR
34
-3
UNH
61
6
TDC
75
4
MRK
22
3
TAP
58
-2
IFF
53
2
ALLE
37
5
DOV
61
-2
QRVO
6
2
PSA
51
-4
HON
65
-2
Financhill
Back

Ascendis Pharma AS 10K Form

Sell
20

ASND
Ascendis Pharma AS

Last Price:
122.73
Seasonality Move:
20.86%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive ASND News And Ratings

See the #1 stock for the next 7 days that we like better than ASND

ASND Financial Statistics

Sales & Book Value

Annual Sales: $288.75M
Cash Flow: $0
Price / Cash Flow: 0
Annual Sales: $-1.82
Price / Book: 0

Profitability

EPS (TTM): -8.10500
Net Income (TTM): $-462.76M
Gross Margin: $240.69M
Return on Equity: 0%
Return on Assets: -48.84%

Ascendis Pharma AS Earnings Forecast

Key Ascendis Pharma AS Financial Ratios

  • The Gross Profit Margin over the past 5 years for ASND is 83.36%.
  • The Selling, General & Administrative Expenses for ASND have been equal to 99.13% of Gross Profit Margin.
  • The Research & Development expenses have been 155.02% of Revenue.
  • The Interest Expense is -9.15% of Operating Income.
  • The Net Earning history of ASND is -180.51% of Total Revenues.
  • Per Share Earnings over the last 12 years have been positive in 4 years.

Ascendis Pharma AS Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: ASND
CUSIP: 04351P
Website: ascendispharma.com

Debt

Debt-to-Equity Ratio: -8.1
Current Ratio: 1.16
Quick Ratio: 0.81

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

ASND Technical Analysis vs Fundamental Analysis

Sell
20
Ascendis Pharma AS (ASND) is a Sell

Is Ascendis Pharma AS a Buy or a Sell?